Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...